<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01511575</url>
  </required_header>
  <id_info>
    <org_study_id>AAML12B3</org_study_id>
    <secondary_id>COG-AAML12B3</secondary_id>
    <secondary_id>AAML12B3</secondary_id>
    <secondary_id>NCI-2012-00111</secondary_id>
    <nct_id>NCT01511575</nct_id>
  </id_info>
  <brief_title>Studying Biomarker Expression in Samples From Patients With Down Syndrome and Acute Myeloid Leukemia or Other Transient Myeloproliferative Disorder</brief_title>
  <official_title>Analysis of MicroRNA Expression in Down Syndrome Acute Myeloid Leukemia and the Transient Myeloproliferative Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood, tissue, and bone marrow from patients with cancer in
      the laboratory may help doctors learn about changes that occur in RNA and identify biomarkers
      related to cancer.

      PURPOSE: This research trial studies RNA samples from patients with Down syndrome and acute
      myeloid leukemia or other transient myeloproliferative disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To compare miRNA expression in distinctive diagnostic groups: transient
           myeloproliferative disorder (TMD), Down syndrome (DS) acute megakaryocytic leukemia
           (AMkL), non-DS AMkL, and in remission DS samples (representing germline, non-malignant
           samples).

      OUTLINE: Archived RNA samples are analyzed for mature micro (mi)RNA expression by real-time
      RT-PCR. Results are then compared with miRNA expression of non-Down syndrome patients with
      acute megakaryocytic leukemia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gene expression levels between DS AMKL and non-DS AMKL patients</measure>
  </primary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RNA analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>reverse transcriptase-polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Down syndrome (DS) diagnosed with acute myeloid leukemia or transient
        myeloproliferative disorder.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Patients with Down syndrome (DS) diagnosed with acute myeloid leukemia or transient
             myeloproliferative disorder

          -  Clinical samples obtained from patients enrolled on the COG AAML0431 and COG AAML08B1

        PATIENT CHARACTERISTICS:

          -  Previously consented to biologic studies

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Taub, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Michigan</affiliation>
  </overall_official>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2012</study_first_submitted>
  <study_first_submitted_qc>January 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2012</study_first_posted>
  <last_update_submitted>May 13, 2016</last_update_submitted>
  <last_update_submitted_qc>May 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia/other myeloid malignancies</keyword>
  <keyword>childhood acute megakaryocytic leukemia (M7)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Down Syndrome</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Leukemoid Reaction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

